Melinda Griffith - 15 Aug 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Reporting relationship: Director
Issuer ticker: OCX
Reported as of: 15 Aug 2022
Net transaction value: +$10,000
SEC form: 4
Accepted by SEC: 17 Aug 2022, 20:18:17 UTC
Prior SEC filing: 19 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Melinda Griffith

Key filing fact

Melinda Griffith filed Form 4 for Oncocyte Corp (OCX) on 17 Aug 2022.

Key facts

This page summarizes Melinda Griffith's Form 4 filing for Oncocyte Corp (OCX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2022, 20:18.

Change

Previous filing in this sequence was filed on 19 Jul 2022.
Current net transaction value: +$10,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCX transaction

Common Stock, no par value

Award

Transaction value: $0
Shares: +10,000
Change %: +100%
Price: $0.000000
Shares after: 20,000
Date: 15 Aug 2022
Ownership: Direct
Footnotes: F1

OCX transaction

Common Stock, no par value

Purchase

Transaction value: $10,000
Shares: +10,000
Change %: +50%
Price: $1.00
Shares after: 30,000
Date: 16 Aug 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCX transaction Derivative

Option to Purchase Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %
Price: $0.000000
Shares after: 45,000
Date: 15 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price: $0.9700
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

Footnote F2

Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.